Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 5 de 5
1.
Proc Natl Acad Sci U S A ; 117(25): 14331-14341, 2020 06 23.
Article En | MEDLINE | ID: mdl-32513686

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with approximately four new cases per 100,000 persons per year. Standard treatment for AML consists of induction chemotherapy with remission achieved in 50 to 75% of cases. Unfortunately, most patients will relapse and die from their disease, as 5-y survival is roughly 29%. Therefore, other treatment options are urgently needed. In recent years, immune-based therapies have led to unprecedented rates of survival among patients with some advanced cancers. Suppression of T cell function in the tumor microenvironment is commonly observed and may play a role in AML. We found that there is a significant association between T cell infiltration in the bone marrow microenvironment of newly diagnosed patients with AML and increased overall survival. Functional studies aimed at establishing the degree of T cell suppression in patients with AML revealed impaired T cell function in many patients. In most cases, T cell proliferation could be restored by blocking the immune checkpoint molecules PD-1, CTLA-4, or TIM3. Our data demonstrate that AML establishes an immune suppressive environment in the bone marrow, in part through T cell checkpoint function.


Bone Marrow/metabolism , Leukemia, Myeloid, Acute/metabolism , T-Lymphocytes/metabolism , Tumor Microenvironment/physiology , Bone Marrow/immunology , CTLA-4 Antigen/metabolism , Cell Proliferation , Cytokines/metabolism , Hepatitis A Virus Cellular Receptor 2/metabolism , Humans , Leukemia, Myeloid, Acute/immunology , Leukemia, Myeloid, Acute/therapy , Programmed Cell Death 1 Receptor/metabolism , T-Lymphocytes/immunology
2.
Mol Cell ; 43(6): 927-39, 2011 Sep 16.
Article En | MEDLINE | ID: mdl-21925381

Alternative intronic polyadenylation (IPA) can generate truncated protein isoforms with significantly altered functions. Here, we describe 31 dominant-negative, secreted variant isoforms of receptor tyrosine kinases (RTKs) that are produced by activation of intronic poly(A) sites. We show that blocking U1-snRNP can activate IPA, indicating a larger role for U1-snRNP in RNA surveillance. Moreover, we report the development of an antisense-based method to effectively and specifically activate expression of individual soluble decoy RTKs (sdRTKs) to alter signaling, with potential therapeutic implications. In particular, a quantitative switch from signal transducing full-length vascular endothelial growth factor receptor-2 (VEGFR2/KDR) to a dominant-negative sKDR results in a strong antiangiogenic effect both on directly targeted cells and on naive cells exposed to conditioned media, suggesting a role for this approach in interfering with angiogenic paracrine and autocrine loops.


Introns , Polyadenylation , Receptor Protein-Tyrosine Kinases/biosynthesis , Humans , Neovascularization, Physiologic/physiology , Poly A/chemistry , Poly A/genetics , Protein Isoforms/biosynthesis , Protein Isoforms/chemistry , Protein Isoforms/physiology , RNA Splicing , Receptor Protein-Tyrosine Kinases/chemistry , Receptor Protein-Tyrosine Kinases/physiology , Ribonucleoprotein, U1 Small Nuclear/physiology , Signal Transduction , Vascular Endothelial Growth Factor Receptor-2/biosynthesis , Vascular Endothelial Growth Factor Receptor-2/chemistry , Vascular Endothelial Growth Factor Receptor-2/physiology
3.
EMBO J ; 30(19): 4084-97, 2011 Sep 13.
Article En | MEDLINE | ID: mdl-21915099

In tumours, aberrant splicing generates variants that contribute to multiple aspects of tumour establishment, progression and maintenance. We show that in glioblastoma multiforme (GBM) specimens, death-domain adaptor protein Insuloma-Glucagonoma protein 20 (IG20) is consistently aberrantly spliced to generate an antagonist, anti-apoptotic isoform (MAP-kinase activating death domain protein, MADD), which effectively redirects TNF-α/TRAIL-induced death signalling to promote survival and proliferation instead of triggering apoptosis. Splicing factor hnRNPH, which is upregulated in gliomas, controls this splicing event and similarly mediates switching to a ligand-independent, constitutively active Recepteur d'Origine Nantais (RON) tyrosine kinase receptor variant that promotes migration and invasion. The increased cell death and the reduced invasiveness caused by hnRNPH ablation can be rescued by the targeted downregulation of IG20/MADD exon 16- or RON exon 11-containing variants, respectively, using isoform-specific knockdown or splicing redirection approaches. Thus, hnRNPH activity appears to be involved in the pathogenesis and progression of malignant gliomas as the centre of a splicing oncogenic switch, which might reflect reactivation of stem cell patterns and mediates multiple key aspects of aggressive tumour behaviour, including evasion from apoptosis and invasiveness.


Brain Neoplasms/metabolism , Gene Expression Regulation, Neoplastic , Glioblastoma/metabolism , Heterogeneous-Nuclear Ribonucleoprotein Group F-H/metabolism , Alternative Splicing , Animals , Cerebral Cortex/metabolism , Death Domain Receptor Signaling Adaptor Proteins/metabolism , Exons , Guanine Nucleotide Exchange Factors/metabolism , HeLa Cells , Humans , MAP Kinase Signaling System , Mice , RNA Splicing , Regulatory Elements, Transcriptional
4.
Bioconjug Chem ; 17(6): 1551-60, 2006.
Article En | MEDLINE | ID: mdl-17105236

Current limitations to applications of monoclonal antibody (mAb) targeted isotope generators in radioimmunotherapy include the low mAb labeling yields and the nonspecific radiation of normal tissues by nontargeted radioimmunoconjugates (RIC). Radiotoxicity occurs in normal organs that metabolize radiolabeled proteins and peptides, primarily liver and kidneys, or in radiosensitive organs with prolonged exposure to the isotope from the blood, such as the bone marrow. Actinium-225 nanogenerators also have the problem of released agar-emitting daughters. We developed two new bifunctional chelating agents (BCA) in order to address these issues. Thiol-maleimide conjugation chemistry was employed to increase the efficiency of the mAb radiolabelings by up to 8-fold. In addition, one bifunctional chelating agent incorporated a cleavable linker to alter the catabolism of the alpha-particle-emitting mAb conjugate. This linker was designed to be sensitive to cathepsins to allow release and clearance of the chelated radiometal after internalization of the radioimmunoconjugate into the cell. We compared the properties of the cleavable conjugate (mAb-DOTA-G3FC) to noncleavable constructs (mAb-DOTA-NCS and mAb-DOTA-SH). The cleavable RIC was able to release 80% of its radioactive payload when incubated with purified cathepsin B. The catabolism of the constructs mAb-DOTA-G3FC and mAb-DOTA-NCS was investigated in vitro and in vivo. RIC integrity was retained at 85% over a period of 136 h in mouse serum in vivo. Both conjugates were degraded over time inside HL-60 cells after internalization and in mouse liver in vivo. While we found that the rates of degradation of the two RICs in those conditions were similar, the amounts of the radiolabeled product residues were different. The cleavable mAb-DOTA-G3FC conjugate yielded a larger proportion of fragments below 6kDa in size in mouse liver in vivo after 12 h than the DOTA-NCS conjugate. Biodistribution studies in mice showed that the mAb-DOTA-G3FC construct yielded a higher liver dose and prolonged liver retention of radioactivity compared to the mAb-DOTA-NCS conjugate. The accumulation in the liver seemed to be in part caused by the maleimide functionalization of the antibody, since the noncleavable mAb-DOTA-SH maleimide-functionalized control conjugate displayed the same biodistribution pattern. These results provide an insight into the catabolism of RICs, by demonstrating that the release of the radioisotope from a RIC is not a sufficient condition to allow the radioactive moiety to clear from the body. The excretion mechanisms of radiolabeled fragments seem to constitute a major limiting step in the chain of events leading to their clearance.


Actinium/metabolism , Actinium/pharmacokinetics , Cross-Linking Reagents/chemical synthesis , Actinium/chemistry , Animals , Cell Line, Tumor , Chelating Agents/chemistry , Drug Delivery Systems , Female , Humans , Immunoconjugates/chemistry , Immunoconjugates/immunology , Mice , Mice, Inbred BALB C , Molecular Structure , Neoplasms , Xenograft Model Antitumor Assays
5.
J Chem Phys ; 121(3): 1578-86, 2004 Jul 15.
Article En | MEDLINE | ID: mdl-15260706

We have investigated the orientation ordering of two shish-kebab chains confined by spherically harmonic potentials through Monte Carlo simulations and asymptotic analysis. The rigid rod is modeled as shish-kebab chains consisting of tangent hard spheres aligned in the same axis, and the harmonic potential is chosen to model nonrigid cavities. We first show that the interactions between a rod and the spherically harmonic potential are independent of chain orientation, indicating that the alignment of two confined rods arises from the excluded volume interactions alone. In the strong fields, the order parameter of two confined rods converges to different values, depending on the parity of chain length. From asymptotic order parameters, we find that the rods of odd-number beads rotate more freely even under the limiting strong confinement. However, the two rods of even-number beads are essentially trapped in a configuration of perpendicular alignment through intercalation of their central grooves. We attribute the dependence of the parity of chain length to the different locations of the center-of-mass in a rod for these two cases. Furthermore, we compare the shish-kebab chains with different rod models in the simulations, and utilize these models to explore the effect of the local rod smoothness on molecular alignment. Our findings suggest that increasing local rod smoothness enhances the rotational degree of freedom for confined rods, and the effect of local rod roughness emerges under strong enough applied potentials.

...